---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008163"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:57:17.113639+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q4/Full Year 2022 Net Loss $58.8M; Phase 3 Trial on Track, FDA Fast Track for Choroidal Metastasis

## Summary
- Net loss of $58.8M for FY2022 vs $35.3M in 2021; cash & securities $188.8M sufficient into 2025.
- FDA granted Fast Track Designation for bel-sar in choroidal metastasis, second ocular oncology indication.
- Global Phase 3 trial in early-stage choroidal melanoma on track to dose first patient in 1H 2023.
- Positive interim Phase 2 data: 100% tumor control rate, statistically significant reduction in growth rate (p<0.0001) at 9-month follow-up.
- Raised $92.5M gross proceeds in oversubscribed follow-on public offering in December 2022.

## SEC filing metadata
- accession: 0000950170-23-008163
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017023008163/0000950170-23-008163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017023008163/aura-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008163
- JSON: https://secwatch.observer/filing/0000950170-23-008163.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008163.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017023008163/0000950170-23-008163-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.